IP-10 antibodies and their uses

US11708405B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Mohan Srinivasan · Cupertino, US
• Shrikant Deshpande · Fremont, US
• Qihong Zhao · Princeton, US
• Huadong Sun · Cambridge, US
• Ginger Rakestraw · Cambridge, US
• Guodong Chen · East Brunswick Township, US
• Richard Y. Huang · Princeton, US
• Steven Sheriff · Princeton, US
• Cristian Rodriguez · Princeton, US
• John P. Throup · New Hope, US
• Rose A. Dibella · Dedham, US

Key dates

• Filing date: Dec 27, 2019
• Grant date: Jul 25, 2023
• Expiry date: Oct 5, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.